Form 4: Jaguar Health Director Jonathan B. Siegel Acquires Stock Options

Jonathan B. Siegel, a director of Jaguar Health, Inc., was granted stock options to purchase 26,500 shares of common stock on October 8, 2024.

Summary

• On October 8, 2024, Jonathan B. Siegel, a director of Jaguar Health, Inc., was granted stock options to purchase 26,500 shares of the company's common stock.
• The options were granted under the company's 2014 Stock Incentive Plan.
• The exercise price of the options is $1.29 per share.
• The options will vest 100% on the first anniversary of the grant date, provided that Mr. Siegel continues to serve on the board of directors of Jaguar Health and its subsidiary, Napo Therapeutics, S.p.A.
• The options expire on October 8, 2034.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing regarding stock option grants, which is generally neutral. It indicates confidence in the company's future, but it's not overwhelmingly positive.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing him to work towards the company's success.
• The vesting schedule encourages continued service on the board of directors.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the director's performance leads to an increase in the company's stock price.

Key Dates

Keywords

stock options, Jaguar Health, director, Jonathan B. Siegel, JAGX, beneficial ownership, Form 4